This is an open-label, nonrandomized phase I trial to determine the safety and maximum tolerated dose of irinotecan with a fixed dose of UFT plus oral leucovorin in patients with advanced or metastatic colorectal cancer.
Rainer Lipp, MD
Advertisement
Articles by Rainer Lipp, MD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on CancerNetwork
1
MYTHIC Trial Demonstrates Efficacy in Platinum-Resistant Ovarian Cancer
2
Selecting Among Preferred 1L Regimens — A Discussion
3
What is the Future of TIL Therapy in Metastatic Melanoma?
4
Novel HP1K Inhibitor Shows Favorable Responses in ccRCC, Solid Tumors
5